Written question asked by Freddie van Mierlo (Liberal Democrat) on Tuesday, 10 March 2026, in the House of Commons. It was due for an answer on Monday, 16 March 2026 (named day). A holding answer was provided on Tuesday, 17 March 2026. A substantive answer was provided by Zubir Ahmed (Labour) on Thursday, 19 March 2026 on behalf of the Department of Health and Social Care.
Donanemab and Lecanemab
- Question
-
To ask the Secretary of State for Health and Social Care, when he expects NICE to publish the outcomes of the appeals on its final draft guidance on donanemab and lecanemab.
- Answer
-
The appeals against the National Institute for Health and Care Excellence (NICE) recommendations on donanemab and lecanemab for the treatment of Alzheimer’s disease were heard by NICE’s independent appeal panel in January. The next steps of the appraisal will be subject to the outcome of the appeals, and NICE will update its stakeholders in due course.
Secondary information
- Type
- Written question
- Reference
- 119738
- Session
- 2024-26
- Subjects
- National Institute for Health and Care Excellence Donanemab Lecanemab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-03-19 11:07:00 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/119738
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/119738
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/119738